All In MedTech

Device Trial Radar · NCT00885677

MOnitoring REsynchronization deviCes and cARdiac patiEnts

Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 918 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

918

Actual

Start

Jun 2009

Primary completion

Dec 2015

Study completion Jan 2016

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2009

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare two different strategies of disease management in heart failure patients treated with cardiac resynchronization therapy devices 1. Remote monitoring with CareLink Network System 2. Standard management of the disease by means of scheduled routine in-patient follow-ups; and to demonstrate that the remote monitoring strategy is superior to the standard strategy, both in terms of clinical effectiveness and total healthcare system utilization.

Conditions

  • Heart Failure

Interventions

  • Medtronic CareLink® NetworkDevice

    Continuous monitoring via a disease remote management system. Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Median Time Between Event Onset Time and Clinical Decision for Each Subject.Time frame: 1 year since the randomization
  2. Phase 2: Combined Endpoint of Death From Any Cause, Cardiovascular and Device-related Hospitalizations (at Least 48 Hours Stay), Calculated as Number of Subjects With at Least One EventTime frame: 2 years after randomization

Locations

64 sites in 10 countries. Site status is shown where the registry gives one.

  • Institut Klinicke a Experimentalni Mediciny

    Prague, Czechia

  • Centre Hospitalier Universitaire de Angers

    Angers, France

  • Hôpital Cardiologique du Haut Lévêque

    Bordeaux, France

61 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.